Cash, Lights, Go: Shanghai Takes On Boston In Latest Policy Appeal To Biopharma
From R&D To Manufacturing Powerhouse?
Developers of antibodies, novel vaccines and cell and gene therapies are all slated to get funding support as Shanghai unleashes a flurry of incentives and policies to lead China’s push to become a global biopharma powerhouse.
You may also be interested in...
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.
From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.